Join the Oncology Voice Network. Join for Free
Bringing the Real Patient Voice to Oncology Decisions

Bringing the Real Patient Voice to Oncology Decisions


Share This Article


Who truly speaks for the patient when they’re not there to speak for themselves?

In this eye-opening episode of Oncology Voice Network, host Dr. Kirk Shepard is joined by Elizabeth Franklin, Head of US Public Affairs and Patient Advocacy for Oncology at Sanofi. Drawing on a career spanning frontline social work, policy, nonprofit advocacy, and industry leadership, Elizabeth Franklin reveals the real reasons the “patient voice” often gets lost when critical decisions are made in cancer care. Go beyond surface-level buzzwords as they unpack where patient advocacy can break through organizational resistance, how early decisions in drug development either open doors or shut them, and why it’s not enough to listen—true impact requires action and systemic redesign. Discover the micro and macro shifts the industry can no longer afford to delay, and what it actually takes to carry real patient insight into rooms of power.

If you care about moving oncology forward, don’t miss this powerful conversation. Tune in now.

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Real-World Evidence in Oncology: Opportunities and Limitations
OVN Avatar Massimo Di Maio, Francesco Perrone, Pierfranco Conte

Real-World Evidence in Oncology: Opportunities and Limitations

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Accelerated drug approvals in oncology: Pros and cons
OVN Avatar Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Oncology approvals in 2020: a year of firsts in the midst of a pandemic
OVN Avatar Laleh Amiri-Kordestani & Richard Pazdur

Oncology approvals in 2020: a year of firsts in the midst of a pandemic

Article
Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved
OVN Avatar Sean X Zhang, MSc , Dean Fergusson, PhD , Jonathan Kimmelman, PhD

Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved

Explore OVN